Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBO vs IMMX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IBO Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

IBO Overall Winner 6-Pillar Tally: IBO 4 – 1 IMMX (1 Tie) Matrix Metrics: IBO 5 – 4 IMMX

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Immix Biopharma, Inc. (IMMX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas IMMX carries 48.6/100 (HOLD) at $7.58 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While IMMX currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBO vs IMMX
IBO NYSE American Head-to-Head Winner
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.96
-3.5% 1D
Market Cap $41.2M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol -6.75β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52
IMMX NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.58
-3.25% 1D
Market Cap $655.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.80β · 84% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 46.0 Fund 55.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.7%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $8.05 · SMA50: $9.69

6-Pillar Scorecard Institutional Category Breakdown (IBO 4 – 1 IMMX)

Columns: Metric · IBO · IMMX
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E 0.4x N/M
PEG Ratio N/M N/M
EV / Revenue 18.2x N/M
2. Growth & Scale IBO
Revenue Growth (YoY) +16.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M N/A
Market Cap $41.2M $655.8M
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin -12621.0% 0.0%
Net Profit Margin 4247.4% 0.0%
Return on Equity (ROE) 71.2% -27.0%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$99M -$39M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.18 Book/Sh · 71.2% ROE $224M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IMMX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 92.6% (17th %ile)
Put/Call OI Skew N/A 1.24x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBO (5) vs IMMX (4)
Institutional Metric IBO IMMX Criterion Row Edge
Market Capitalization
Scale
$41.2M $655.8M Larger Scale IMMX
Trailing P/E Ratio
Valuation
0.4x N/M Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+16.7% +0.0% Higher Growth IBO
Operating Margin (TTM)
Profitability
-12621.0% 0.0% Higher Margin IMMX
Net Profit Margin
Profitability
4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
71.2% -27.0% Higher ROE IBO
52-Week Range Position
Momentum
68% ($0–$7) 36% ($3–$15) Stronger Trend IBO
Beta / 30D Volatility
Risk Regime
-6.75β · 120% Vol 1.80β · 84% Vol Lower Realized Risk IMMX
Unified Institutional Score
Composite Signal
36.8 / 100 (SELL) 48.6 / 100 (HOLD) Higher Composite IMMX
Trailing 12M Revenue (USD)
Operating Scale
$2.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 18.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$99M ($1.18 Book/Sh · 71.2% ROE) -$39M ($224M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +90.02 pp
IBO: +85.07% · IMMX: -4.95%
3M Horizon IBO +991.09 pp
IBO: +955.32% · IMMX: -35.77%
6M Horizon IBO +837.05 pp
IBO: +821.42% · IMMX: -15.63%
1Y Horizon IBO +762.44 pp
IBO: +872.55% · IMMX: +110.11%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs IMMX. Trailing 12-month operating profitability (IBO -12621.0% vs IMMX 0.0%) and valuation multiples (IBO N/M vs IMMX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IBO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross MarginN/A
Op. Margin-12621.0%
ROE / Fwd P/E71.2% · N/M
IMMX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-27.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IMMX BREAKDOWN
58d in phase · OBV ACCUMULATION
Current IV 92.6%
IV Percentile 17th %ile
Put/Call OI Skew 1.24x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact IMMX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $41.2M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IMMX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $655.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBO vs IMMX Key Questions & Quantitative Answers

As of Nov 16, 2026, Impact BioMedical, Inc. (IBO) is the stronger overall head-to-head candidate over Immix Biopharma, Inc. (IMMX) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IBO carries a Unified Composite Score of 36.8/100 (SELL) at $4.96 (N/M Forward P/E, -12621.0% operating margin), whereas IMMX carries 48.6/100 (HOLD) at $7.58 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While IMMX currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. IBO 36.8/100 SELL), IBO captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-12621.0% vs. 0.0% operating margin) and revenue trajectory (+16.7% vs. +0.0% YoY). Technical & Structure Timing Caution: IBO trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.4); meanwhile IMMX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBO leads the Growth & Scale pillar: IBO posts +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (N/A gross margin, -12621.0% operating margin), compared with IMMX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, IBO generates $2.3M in USD-normalized revenue versus N/A for IMMX. In operating R&D and SG&A reinvestment, IBO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMMX.

IBO screens cheaper on headline valuation multiples. IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 18.2x EV/Revenue (unreported FCF margin), whereas IMMX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBO (71.2% ROE) versus IMMX (-27.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.75β · 120% Vol realized risk). By comparison, IMMX carries 92.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.24x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.80β · 84% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.